Anti-c-RET / Ret proto-oncogene, clone r3F8

1 mg/ml in 1X PBS, BSA free, sodium azide free. RET Proto-Oncogene antibody, also known as Colorectal Cancer Marker antibody, recognizes RET, a receptor tyrosine kinase encoded by the human RET gene on chromosome 10q11.21. RET is a transmembrane protein that mediates signaling in response to glial cell line-derived neurotrophic factor family ligands through association with GFR alpha co-receptors. The receptor contains extracellular cadherin-like domains, a single-pass transmembrane region, and an intracellular tyrosine kinase domain that undergoes autophosphorylation upon activation. RET Proto-Oncogene antibody targets a protein primarily localized to the plasma membrane with additional cytoplasmic distribution following receptor internalization.Activation of RET initiates downstream signaling cascades including MAPK, PI3K-AKT, and STAT pathways, regulating cellular proliferation, survival, migration, and differentiation. While RET signaling is essential for neural crest development, kidney morphogenesis, and enteric nervous system formation, aberrant RET activation contributes to oncogenesis. Germline and somatic RET alterations are well established in thyroid carcinomas and lung cancers. Increasing evidence also supports a role for RET pathway activation in subsets of colorectal carcinoma, where receptor tyrosine kinase signaling contributes to tumor progression and therapeutic resistance.In colorectal cancer, dysregulated receptor tyrosine kinase networks influence tumor growth, invasion, and response to targeted therapies. RET expression in colorectal carcinoma tissue has been investigated as a potential biomarker and therapeutic target, particularly in tumors exhibiting altered kinase signaling profiles. Membranous and cytoplasmic RET expression may reflect active or dysregulated receptor signaling within malignant epithelial cells.RET Proto-Oncogene antibody is suitable for detecting RET expression in studies of solid tumor biology and kinase-driven malignancies. Recombinant monoclonal clone r3F8 is generated using defined expression systems to promote consistency and reproducibility in research applications. A Colorectal Cancer Marker antibody such as clone r3F8 supports investigation of RET signaling dynamics, tumor-associated expression patterns, and receptor tyrosine kinase involvement in colorectal carcinoma.